T cell receptor alpha joining 29 (TRAJ29)

TRAJ29 is a joining (J) gene segment of the human T cell receptor (TCR) alpha chain locus. It participates in the process of somatic recombination (V-J joining) to generate the variable domain of the TCR alpha chain during T cell development. This process, alongside TRAV (variable) gene segments, enables the incredible diversity necessary for T cells to recognize a broad array of foreign antigens presented by major histocompatibility complex (MHC) molecules. However, TRAJ29 itself does not encode a receptor or partner with drugs, nor does it serve as a direct disease marker or therapeutic target. Instead, it is one of many genetic elements creating the repertoire of receptors involved in adaptive cellular immunity. Key context: - The products of recombined TRAV and TRAJ genes form the variable region of the TCR alpha chain, which—along with the beta chain—forms the functional T cell receptor on T lymphocytes. - The functional TCR is a receptor and a major lymphocyte target for therapeutic intervention, but TRAJ29 alone is a genetic building block, not a surface molecule or protein. - This term is often listed in immunogenetic databases (such as UniProt and GeneCards) as a segment used for annotation and analysis of T cell receptor repertoire diversity. Summary: TRAJ29 should not be considered a drug target or molecular entity for structured pharmacological annotation. It is best classified as a genetic segment contributing to antigen receptor diversity within the adaptive immune system.

Other names

TRAJ29